Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00697801 · ClinicalTrials.gov registry record · Phase 2
Study of MAP0010 in Asthmatic Children and Adolescents
A Phase 2 study of Asthma, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 208
- Enrollment target
- 1
- Study location
NCT00697801 is a Phase 2 study of Asthma that has completed, run by Allergan. The registered enrollment target is 208 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00697801, a Phase 2 study of Asthma, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 208 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this study are to evaluate the efficacy, tolerability and pharmacokinetics of 2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MAP0010 low dose
- DRUG MAP0010 high dose
Study Locations (1)
California
- - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2006-07 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00697801
The ClinicalTrials.gov registry entry for NCT00697801 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (87% lower). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00697801 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00697801 about?
NCT00697801 is a clinical study titled "Study of MAP0010 in Asthmatic Children and Adolescents". The objectives of this study are to evaluate the efficacy, tolerability and pharmacokinetics of 2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents.
What is the current status of trial NCT00697801?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 208 participants. The study started on 2006-07. Estimated completion is 2006-12.
What conditions does trial NCT00697801 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00697801?
The interventions under investigation include: Placebo (DRUG), MAP0010 low dose (DRUG), MAP0010 high dose (DRUG).
Who is sponsoring clinical trial NCT00697801?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00697801 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.